1988
The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment.
Young R, Longo D, Glatstein E, Ihde D, Jaffe E, DeVita V. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Seminars In Hematology 1988, 25: 11-6. PMID: 2456618.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyCyclophosphamideDoxorubicinEtoposideEvaluation Studies as TopicHumansLeucovorinLeukemiaLeukemia, Radiation-InducedLymph NodesLymphoma, Non-HodgkinMechlorethamineMethotrexateNeoplasms, Multiple PrimaryNeoplasms, Radiation-InducedPalliative CarePrednisoneProcarbazineRandom AllocationVincristineConceptsAdvanced indolent lymphomaLimited radiation therapyTotal nodal irradiationIndolent lymphomaRadiation therapyModality treatmentInitial treatmentAggressive combined modality therapyCombined modality therapyEvaluable patientsInduction therapyInitial therapyNodal irradiationFirst remissionInitial remissionFrequent relapsesMedian durationModality therapySystemic therapyCombination chemotherapyMedian timeHistologic progressionLonger survivalPatient's diseasePatients
1983
Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy.
Fisher R, DeVita V, Hubbard S, Longo D, Wesley R, Chabner B, Young R. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. Annals Of Internal Medicine 1983, 98: 304-9. PMID: 6600902, DOI: 10.7326/0003-4819-98-3-304.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBlood PlateletsCyclophosphamideDoxorubicinDrug Administration ScheduleDrug Therapy, CombinationEtoposideFemaleHumansLeucovorinLeukopeniaLymphomaMaleMechlorethamineMethotrexateMiddle AgedPrednisoneProcarbazineVincristineConceptsComplete remission rateDiffuse aggressive lymphomasMOPP chemotherapyRemission rateAggressive lymphomaDose-limiting toxicityRelapse-free survivalNew treatment programPhases of treatmentComplete remissionComplete respondersMedian durationMedian survivalUntreated patientsTumor responsePatient rateLate intensificationPatientsAdvanced stageChemotherapyTreatment programSurvivalLymphoma
1979
Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse.
Fisher R, DeVita V, Hubbard S, Simon R, Young R. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Annals Of Internal Medicine 1979, 90: 761-3. PMID: 434676, DOI: 10.7326/0003-4819-90-5-761.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseProlonged disease-free survivalDisease-free survivalLong-term survivalMOPP chemotherapyMOPP therapyComplete remissionMedian survivalMedian durationRe-treatmentMOPPRemissionHodgkinPatientsRelapseReinductionNitrogen mustardMonthsSurvivalDiseasePrednisoneDurationProcarbazineChemotherapyVincristine
1978
Hexamethylmelamine in alkylating agent‐resistant ovarian carcinoma
Johnson B, Fisher R, Bender R, Devita V, Chabner B, Young R. Hexamethylmelamine in alkylating agent‐resistant ovarian carcinoma. Cancer 1978, 42: 2157-2161. PMID: 102417, DOI: 10.1002/1097-0142(197811)42:5<2157::aid-cncr2820420511>3.0.co;2-7.Peer-Reviewed Original ResearchConceptsDose modificationOvarian cancerDiscontinuation of therapyAdvanced ovarian cancerMedian durationObjective responseAgent therapyProspective studyOvarian carcinomaDay courseSevere toxicityPatientsAttractive agentTherapyToxic effectsHexamethylmelamineCancerDegree of toxicityToxicityActive agentsDiscontinuationChemotherapyNeurologicCarcinomaHematologic
1976
Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma.
Schein P, DeVita V, Hubbard S, Chabner B, Canellos G, Berard C, Young R. Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Annals Of Internal Medicine 1976, 85: 417-22. PMID: 61732, DOI: 10.7326/0003-4819-85-4-417.Peer-Reviewed Original ResearchConceptsHistiocytic lymphomaAdvanced diffuse histiocytic lymphomaExtended disease-free survivalMixed histiocytic-lymphocytic lymphomaNew combination chemotherapy programHistiocytic-lymphocytic lymphomaPrednisone combination chemotherapyCompletion of therapyDiscontinuation of treatmentCombination chemotherapy programsDisease-free survivalDiffuse histiocytic lymphomaBone marrow functionMyelosuppressive phaseComplete remissionMedian durationChemotherapy programCombination chemotherapyComplete responseMarrow functionTumor recurrenceTreatment cyclesFatal diseasePatientsLymphoma
1975
Results of combination chemotherapy of non-Hodgkin's lymphoma.
Schein P, Chabner B, Canellos G, Young R, Berard C, DeVita V. Results of combination chemotherapy of non-Hodgkin's lymphoma. British Journal Of Cancer. Supplement 1975, 2: 465-73. PMID: 1101932, PMCID: PMC2149606.Peer-Reviewed Original ResearchConceptsComplete remissionHodgkin's lymphomaCombination chemotherapyHistological subgroupsLymphocytic lymphomaMonths of treatmentDiffuse histiocytic lymphomaMOPP chemotherapyMedian durationLate recurrenceLymph nodesNodular histologyHistiocytic lymphomaRemissionExtended survivalBone marrowClinical validityLymphomaAdvanced stageChemotherapyPatientsRelapseInitial siteMonthsSurvivalDibromomannitol in the treatment of chronic granulocytic leukemia: a prospective randomized comparison with busulfan.
Canellos G, Young R, Neiman P, DeVita V. Dibromomannitol in the treatment of chronic granulocytic leukemia: a prospective randomized comparison with busulfan. Blood 1975, 45: 197-203. PMID: 1054609, DOI: 10.1182/blood.v45.2.197.bloodjournal452197.Peer-Reviewed Original ResearchConceptsTreatment of chronic granulocytic leukemiaBusulfan-treated patientsChronic granulocytic leukemiaGranulocytic leukemiaMedian duration of disease controlChronic phase of CGLDuration of disease controlContinuous maintenance therapyElevated leukocyte countTreated with busulfanIncreased skin pigmentationMyelosuppressive actionRemission inductionMaintenance therapyMedian survivalMedian durationBlastic transformationPulmonary fibrosisBusulfanRandomized comparisonChronic phaseLeukocyte countDibromomannitolPatientsCytological dysplasiaDibromomannitol in the Treatment of Chronic Granulocytic Leukemia: A Prospective Randomized Comparison With Busulfan
Canellos G, Young R, Nieman P, DeVita V. Dibromomannitol in the Treatment of Chronic Granulocytic Leukemia: A Prospective Randomized Comparison With Busulfan. Blood 1975, 45: 197-203. DOI: 10.1182/blood.v45.2.197.197.Peer-Reviewed Original ResearchTreatment of chronic granulocytic leukemiaBusulfan-treated patientsChronic granulocytic leukemiaGranulocytic leukemiaRandomized comparisonMedian duration of disease controlChronic phase of CGLDuration of disease controlContinuous maintenance therapyElevated leukocyte countTreated with busulfanProspective randomized comparisonIncreased skin pigmentationMyelosuppressive actionRemission inductionMedian survivalMaintenance therapyMedian durationBlastic transformationPulmonary fibrosisBusulfanChronic phaseLeukocyte countDibromomannitolPatients
1974
Chemotherapy of advanced ovarian carcinoma: A prospective randomized comparison of phenylalanine mustard and high dose cyclophosphamide
Young R, Canellos G, Chabner B, Schein P, Hubbard S, DeVita V. Chemotherapy of advanced ovarian carcinoma: A prospective randomized comparison of phenylalanine mustard and high dose cyclophosphamide. Gynecologic Oncology 1974, 2: 489-497. PMID: 4376998, DOI: 10.1016/0090-8258(74)90059-6.Peer-Reviewed Original ResearchConceptsAdvanced ovarian carcinomaComplete remissionMedian durationOvarian carcinomaLong-term disease-free survivalTerm disease free survivalHigh-dose cyclophosphamideDisease-free survivalProspective Randomized ComparisonDose cyclophosphamideIntravenous cyclophosphamideIntensive regimenMelphalan therapyFree survivalInitial remissionMedian survivalUnacceptable toxicityUntreated patientsAgent therapyRandomized comparisonPresent studyHigh dosePhenylalanine mustardRemissionChemotherapyThrombocytosis in Chronic Granulocytic Leukemia: Incidence and Clinical Significance
Mason J, DeVita V, Canellos G. Thrombocytosis in Chronic Granulocytic Leukemia: Incidence and Clinical Significance. Blood 1974, 44: 483-487. PMID: 4528824, DOI: 10.1182/blood.v44.4.483.483.Peer-Reviewed Original ResearchConceptsChronic granulocytic leukemiaPlatelet countGranulocytic leukemiaClinical significanceOccurrence of thrombocytosisElevated platelet countThrombohemorrhagic complicationsUntreated patientsMedian durationShorter survivalBlastic crisisNormal countsPatientsSubsequent courseThrombocytosisLeukemiaCountEntire courseGroupCourseComplicationsClinicIncidenceDiagnosisCyclical Combination Chemotherapy for Advanced Breast Carcinoma
Canellos G, Devita V, Gold G, Chabner B, Schein P, Young R. Cyclical Combination Chemotherapy for Advanced Breast Carcinoma. The BMJ 1974, 1: 218. PMID: 4818162, PMCID: PMC1633086, DOI: 10.1136/bmj.1.5901.218.Peer-Reviewed Original ResearchConceptsMedian survivalMetastatic lesionsAdvanced metastatic breast cancerCyclical combination chemotherapyOverall median durationAdvanced breast carcinomaBone marrow involvementMetastatic breast cancerMetastasis-free intervalSoft tissueExtensive radiotherapyPrevious chemotherapyComplete remissionHaematological toxicityHormonal therapyLiver dysfunctionMarrow involvementMedian durationCombination chemotherapyEndocrine ablationBreast carcinomaBreast cancerPatientsMonthly cyclesChemotherapyPotential for Prolonged Disease-free Survival Following Combination Chemotherapy of Non-Hodgkin’s Lymphoma
Schein P, Chabner B, Canellos G, Young R, Berard C, DeVita V. Potential for Prolonged Disease-free Survival Following Combination Chemotherapy of Non-Hodgkin’s Lymphoma. Blood 1974, 43: 181-189. PMID: 4589318, DOI: 10.1182/blood.v43.2.181.181.Peer-Reviewed Original ResearchConceptsComplete remissionMedian survivalCombination chemotherapyHodgkin's lymphomaExtended disease-free survivalDisease-free survivalImproved median survivalNon-Hodgkin lymphomaMOPP chemotherapyMedian durationFurther therapyNodular histologyHistologic subgroupsDiffuse histologyHistologic categoriesNodular patternAggressive subgroupClinical validityLymphomaAdvanced stageRemissionChemotherapyEntire groupPatientsSignificant differences
1973
MAINTENANCE CHEMOTHERAPY FOR ADVANCED HODGKIN'S DISEASE IN REMISSION
Young R, Chabner B, Canellos G, Schein P, Devita V. MAINTENANCE CHEMOTHERAPY FOR ADVANCED HODGKIN'S DISEASE IN REMISSION. The Lancet 1973, 301: 1339-1343. PMID: 4122739, DOI: 10.1016/s0140-6736(73)91672-3.Peer-Reviewed Original ResearchConceptsMaintenance therapyIntermittent therapyAdvanced HodgkinMaintenance chemotherapyAdditional therapyComplete remissionInitial remissionMedian durationFurther therapyHodgkin's diseasePatientsTherapyRemissionEntire groupDiseaseChemotherapySignificant differencesSurvivalGroupPrednisoneRegimensComplicationsMustineVincristineInfection